[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"left-ventricle-dilated\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:left-ventricle-dilated":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100578632","relive-randomized-evaluation-of-less-invasive-ventricular-enhancement-trial-100578632",false,"NCT06813820","RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial","RELIVE","Inclusion Criteria:\n\n1. 18 years old or older\n2. LV Aneurysm or Scar Presence: Defined by presence of a contiguous acontractile (akinetic and\u002For dyskinetic) non-calcified scar\n3. LV Aneurysm\u002FScar Location: Defined as a scar involving anterior, apical or anterolateral ± septal regions of the left ventricle as evidenced by cardiac imaging (Viability of myocardium in regions remote from area of intended scar exclusion as evidenced by cardiac imaging)\n4. Left Ventricular Ejection Fraction \\\u003C 40%\n5. Left ventricular end-systolic volume index ≥60 mL\u002Fm2\n6. Suffering from heart failure symptoms as defined by NYHA Classification \\> 2 not responsive to medical therapy\n7. Patient completed 6 Minute Walk Test and KCCQ Quality of Life Questionnaire (can be performed at baseline visit)\n8. Patient is on adequate Guideline Directed Medical Therapy (GDMT)\n9. Subject or a legally authorized representative must provide written informed consent\n10. Agree to required follow-up visits\n11. Female subject of childbearing potential does not plan pregnancy for at least one year following the index procedure. For a female of childbearing potential, a pregnancy test must be performed with negative results known within seven days prior to index procedure\n\nExclusion Criteria:\n\nCandidates will be excluded from the study if ANY of the following conditions is present:\n\n1. Cardiac Resynchronization Therapy (CRT) or ICD pacing lead placement ≤ 90 days prior to enrollment\n2. Valvular heart disease, which in the opinion of the investigator, will require intervention (transcatheter or surgical)\n3. Mitral Regurgitation greater than moderate (\\>2+)\n4. Need for coronary revascularization, in the opinion of the investigator\n5. Peak Systolic Pulmonary Arterial Pressure \\> 70 mm Hg via echo or right heart catheterization\n6. Myocardial Infarction within 90 days prior to enrollment\n7. Within the last six months, a prior CVA or TIA, or intracranial hemorrhage\n8. Co-morbid disease process with life expectancy of less than one year or active malignancy not in remission\n9. Severe pulmonary disease that would preclude general anesthesia\n10. Any solid organ transplant or is on waiting list for any solid organ transplant other than cardiac\n11. Chronic renal failure with a GFR\\\u003C30ml\u002Fmin\n12. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint","ALL","18 Years",{"count":19,"type":20},135,"ESTIMATED","INTERVENTIONAL",[23],"NA","A prospective, multi-center randomized trial comparing the Revivent System plus GDMT to GDMT alone. A total of approximately 135 subjects will be randomized in a 2:1 allocation ratio (90 treatment and 45 control), with approximately 128 evaluable patients and assuming 5% loss to follow-up. A primary safety endpoint will be evaluated at 30 days. Primary efficacy endpoint will be at 1 year. Interim efficacy endpoints will be evaluated at 6 months.",[26,27,28],"Left Ventricle Remodeling","Left Ventricle Dilated","CHF",[30],"Left Ventricle Reverse remodeling","RECRUITING","2026-02-19",{"date":34,"type":35},"2026-02-20","ACTUAL",{"date":37,"type":35},"2025-09-29",{"date":39,"type":20},"2032-08",{"name":41,"class":42},"BioVentrix","INDUSTRY",6,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":5},"100577973","left-ventricular-reverse-remodeling-evaluation-after-surgical-correction-of-aortic-regurgitation-100577973","NCT06805253","Left Ventricular Reverse Remodeling Evaluation After Surgical Correction of Aortic Regurgitation","Left Ventricular Reverse Remodeling Outcomes Evaluation in Patients With Aortic Regurgitation After Surgical Treatment","ORMIX","Inclusion Criteria:\n\n* Age over 18 years\n* Planned primary elective surgery for chronic aortic regurgitation\n* Presence of functional mitral regurgitation\n* End-diastolic volume of the left ventricle \\>= 250 ml\n\nExclusion Criteria:\n\n* Infectious endocarditis\n* History of myocardial infarction\n* Indications on simultaneous myocardial revascularisation\n* Acute aortic regurgitation of any etiology\n* Previously diagnosed dilatation of the left ventricle, not associated with the development of aortic regurgitation\n* Long-term persistent or permanent form of atrial fibrillation\n* Pregnancy in the first 12 months after surgery\n* Simultaneous participation in other studies\n* Presence of implanted pacemakers\n* Refusal to sign informed consent\n* Acute coronary event diagnosed within 12 months after aortic valve surgery\n* Indications for resynchronization therapy or permanent right ventricular pacing in the first 12 months after aortic valve surgery\n* Re-do cardiac surgery for any reason within 12 months after aortic valve surgery",{"count":53,"type":20},120,"OBSERVATIONAL","Investigators assume that surgical correction approach to functional mitral regurgitation during intervention for chronic aortic regurgitation in patients with severe enlargement of the left heart chambers influences reverse remodeling of the left ventricle (LV) in the postoperative period. It is suggested that functional mitral regurgitation (MR) provides supra-physiological left ventricle volume overload and this fact plays positive role in early-stage post-operative left ventricle volume and function recovery. LV volume, systolic and diastolic function will be monitored with echocardiography (EchoCG) along with life quality in patients with different grades of functional mitral regurgitation secondary to severe chronic aortic insufficiency after surgical treatment of aortic regurgitation.",[57,58,27,59,60,61],"Aortic Valve Regurgitation","Mitral Valve Regurgitation","Left Atrium Dilated","Systolic Left Ventricular Heart Failure","Diastolic Heart Failure",[63,64,65,66],"reverse remodeling","left ventricle dilatation","mitral valve functional regurgitation recovery","left ventricle reverse remodeling","2025-06-05",{"date":69,"type":35},"2025-06-11",{"date":71,"type":35},"2024-05-09",{"date":73,"type":20},"2030-05",{"name":75,"class":76},"Petrovsky National Research Centre of Surgery","OTHER"]